Health4 min(s) read
Major breakthrough as new pill sees deadliest cancer 'vanish' in patients
Experts are calling a daily pill the biggest breakthrough in pancreatic cancer treatment for decades after early clinical trials showed the drug could shrink and even eliminate tumors in some patients.
In the study, cancer became undetectable on scans in one in 12 patients who received the medication, called daraxonrasib, alongside standard chemotherapy drugs gemcitabine and nabpaclitaxel.
The early medical trial included 61 participants who had recently been diagnosed with advanced pancreatic cancer that had already spread to other parts of the body. Tumors stopped growing in almost all of the patients involved in the study.
However, physicians warn that it remains unclear how long the medication can keep the disease at bay, emphasizing that the treatment should not be viewed as a cure.
Pancreatic cancer is notoriously difficult to treat and has the lowest survival rate of all common cancers in the UK. While standard chemotherapy can shrink tumors slightly, the cancer often grows back quickly, and most patients with advanced disease survive for only months rather than years.
Doctors hope this new pill can offer patients valuable extra time, even if it cannot stop the disease permanently.
Promising results from early trials
Cancer Research UK described the development as "the biggest leap forward in decades" for people living with pancreatic cancer.
Speaking to BBC News, the charity's Dr. Sam Godfrey said the findings were incredibly exciting. "What this new drug has done is it's found a way of drugging the undruggable," Dr. Godfrey said. "We are finally seeing progress in pancreatic cancer, which is so long overdue."
During the phase I/II trial, researchers tracked patients for an average of a year and a half, and several participants did not see their cancer return during that timeframe.
Overall, tumors stopped growing in 90% of patients, while just over 60% saw their tumors shrink or disappear completely. For around 8% of participants, or one in 12 patients, tumors became completely undetectable on CT scans.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center in the US, who was involved in the trial, said the early outcomes were very encouraging. "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," he said.
Longer studies are still required to determine if any of these cancers can be placed into lasting remission.
How the targeted therapy works
Daraxonrasib is a targeted inhibitor treatment that has already received approval in the US. The pill functions by locking onto and shutting off specific genetic mutations, known as RAS, which are present in most pancreatic cancers and drive tumor growth.
Because dozens of other cancers, including lung and ovarian cancers, can carry similar mutations, researchers believe the medication could eventually benefit a much wider group of patients.
Dr. Godfrey expressed optimism about the broader potential of the therapy. "I would hope that the early success that we are beginning to see in pancreatic cancer can also be rolled out to other cancers," he said.
Still, he cautioned that extended trials are essential to confirm long-term outcomes. "Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed."
The findings are being presented to fellow physicians at the EORTC-NCI-AACR Symposium 2026 in Europe. Conference chair Prof. Elena Garralda highlighted the potential impact of the combination therapy. "These results are exciting because they show the combined treatment could potentially significantly improve patients' overall survival, as well as the time before tumours start to grow again," she said.
Understanding the impact of pancreatic cancer
The urgency for better treatments is reflected in global mortality statistics. In the United States, pancreatic cancer makes up roughly 3% of all cancer cases but causes about 8% of all cancer deaths, claiming around 53,000 lives annually.
In Britain, Cancer Research UK reports 11,500 new diagnoses and approximately 10,200 deaths each year. The disease has claimed the lives of many high-profile figures, including actor Alan Rickman, who died in 2016 just five months after his diagnosis.
Early detection remains a major challenge, as symptoms can be subtle or easily mistaken for other conditions. Common warning signs include jaundice, itchy skin, darker urine, paler stools, unexplained weight loss, persistent tiredness, and a high temperature.
While more research is needed before daraxonrasib is hailed as a definitive answer, specialists view these trial results as a vital step forward against a devastating disease.













